BCDA

Insider trade Purchase by Altman Peter (President and CEO)

11d ago

Insider trade Purchase by Altman Peter (President and CEO)

11d ago

Insider trade Purchase by Altman Peter (President and CEO)

14d ago

Insider trade Purchase by Altman Peter (President and CEO)

17d ago

News BioCardia outlines Japan Shonin filing in ~7 months and targets ~19-month path to approval for CardiAMP

17d ago

SEC filing BCDA Reports Q1 2026 Net Loss $2.3M, Cash $0.95M

18d ago

Insider trade Purchase by Peter Altman (President and CEO)

33d ago

Insider trade Purchase by Peter Altman (President and CEO)

39d ago

Insider trade Purchase by Peter Altman (President and CEO)

40d ago

SEC filing BCDA Delisted: $895K Equity Below $2.5M Nasdaq Minimum, 180-Day Plan Deadline May 25, 2026

47d ago

News BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit

69d ago

SEC filing BCDA Reports $12.4M Revenue, $0.08 EPS, Announces CardiAMP HF II Trial Expansion, Japan PMDA Consultation, Euro PCR Presentation

69d ago

Insider trade Purchase by Peter Altman (President and CEO)

104d ago

Insider trade Purchase by Peter Altman

104d ago

SEC filing BCDA Completes Pre-Submission Under Q-Subm Process

112d ago

SEC filing Other Events

119d ago

Short volume Short volume 78% of volume (3.6σ)

125d ago

SEC filing BCDA Advances CardiAMP Heart Failure Cell Therapy, Progresses to PMDA Consultation in Japan

168d ago